Login
MannKind Corporation NASDAQ: MNKD
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
| Name | MannKind Corporation |
| Ticker | MNKD |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 1.85 |
| 52W Low/High | 0.84 / 2.21 |
| Market cap | 394 M |
| 1Y Total Return |
48.00%
Strong |
| 1Y Volatility |
74.10%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
Details
| Ticker | MNKD |
| Name | MannKind Corporation |
| ISIN | |
| CUSIP | 56400P201 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/25/20
| Close Price | 1.85 |
| 52W Low/High | 0.84 / 2.21 |
| Market cap | 394 M |
| 1Y Total Return |
48.00%
Strong |
| 1Y Volatility |
74.10%
More Risk |
| Beta | 0.54 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -71.4% |
| Cash from Op. / Cur. Liabilities | -1.06 |
| Diluted Earnings / Share | -0.21 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 6.4 |
| Price / Book | -2.2 |
| Price / CF | -5.5 |
| Current Ratio | 1.1 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
62
|
53
|
14
|
180
|
0
|
0
|
|
| Gross Profit |
33
|
30
|
-
|
131
|
-
|
-
|
|
| R&D |
7
|
6
|
13
|
12
|
22
|
54
|
|
| EBITDA |
-29
|
-51
|
-103
|
148
|
-336
|
-92
|
|
| Operating Income |
-36
|
-57
|
-101
|
58
|
-333
|
-114
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
129
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
214
|
188
|
140
|
100
|
91
|
80
|
|
| EPS exc. Extra |
-0.21
|
-0.35
|
-1.01
|
1.36
|
-4.41
|
-1.65
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
103
|
82
|
62
|
79
|
139
|
353
|
|
| Cash, Eq & Invt ShortTerm |
64
|
38
|
27
|
43
|
64
|
107
|
|
| Total Current Assets |
73
|
50
|
36
|
51
|
91
|
146
|
|
| Total Non-Current Assets |
30
|
32
|
26
|
28
|
49
|
207
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
282
|
278
|
269
|
301
|
506
|
468
|
|
| Total Current Liabilities |
68
|
77
|
75
|
86
|
290
|
342
|
|
| Long Term Debt |
215
|
201
|
194
|
215
|
216
|
126
|
|
| Shareholder equity |
-180
|
-196
|
-207
|
-221
|
-367
|
-115
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-72
|
-20
|
-102
|
-47
|
-85
|
50
|
|
| Depreciation |
2
|
3
|
3
|
4
|
9
|
13
|
|
| Cash from Investing |
23
|
-27
|
0
|
17
|
-3
|
-23
|
|
| Capex |
1
|
2
|
0
|
0
|
3
|
23
|
|
| Cash from Financing |
99
|
33
|
85
|
10
|
44
|
39
|
|
| Stock Issued |
31
|
44
|
90
|
0
|
115
|
34
|
|
| Debt (LT) Issued |
70
|
-8
|
0
|
10
|
-65
|
40
|
|
| Free Cash Flow |
-40
|
-61
|
-82
|
-94
|
-369
|
83
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
71.6%
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-81.4%
|
-
|
-
|
|
| Current Ratio |
1.1
|
0.6
|
0.5
|
0.6
|
0.3
|
0.4
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available